BOSTON MEDICAL CENTER CORPORATION Patent applications |
Patent application number | Title | Published |
20150299778 | PRIMERS, PROBES, AND METHODS FOR MYCOBACTERIUM TUBERCULOSIS SPECIFIC DIAGNOSIS - Practical and rapid methods for the diagnosis of | 10-22-2015 |
20150183848 | TREATMENT OF lge-MEDIATED DISEASE - The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble CD23 (sCD23) that binds and sequesters IgE. Thus, the sCD23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased IgE levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers. | 07-02-2015 |
20140255444 | COMPOSITIONS AND METHODS FOR TREATING EBOLA VIRUS INFECTION - The compositions and methods of the invention described herein provide treatments against Ebola virus infection by expressing gene(s) from the Ivory Coast ebolavirus (ICEBOV) species in a recombinant viral vector. | 09-11-2014 |
20140173777 | METHODS FOR ELEVATING FAT/OIL CONTENT IN PLANTS - In some embodiments, the present invention provides a method of elevating lipid content in vegetative (non-seed) plant or algae cells, plant tissues, or whole plants by genetically modifying the plant or algae to express a lipid droplet-associated protein or polypeptide (such as fat-specific protein 27) of mammalian origin. Also provided are genetically-modified plant or algae cells, plant tissues, or whole plants with elevated cellular lipid content, expressing a lipid droplet-associated protein or polypeptide (such as fat-specific protein 27) of mammalian (e.g. human) origin. | 06-19-2014 |
20130281525 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS - Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness. | 10-24-2013 |
20130039934 | TREATMENT OF IGE-MEDIATED DISEASE - The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble CD23 (sCD23) that binds and sequesters IgE. Thus, the sCD23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased IgE levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers. | 02-14-2013 |
20120214169 | DIFFERENTIAL LEVELS OF HAPTOGLODIN ISOFORMS IN SMALL CELL LUNG CANCER - The invention is directed to protein or nucleic acid assays for diagnosis, prognosis and monitoring of lung cancers, in particular small cell lung cancer using biomarkers comprising haptoglobin isoforms, or fragments or variants thereof. | 08-23-2012 |
20110236966 | SINGLE LENTIVIRAL VECTOR SYSTEM FOR INDUCED PLURIPOTENT (IPS) STEM CELLS DERIVATION - The present invention is based on the discovery that a single lentiviral vector expressing multiple individual transcription factor proteins from a single multi-cistronic mRNA can reprogram a fibroblast cell to a stem cell-like cell. These reprogrammed induced pluripotent stem (iPS) cells are pluripotent. Additions of the Cre-LoxP sequences into the single lentiviral vector facilitate excision of the vector after reprogramming in achieved. Addition of a maker gene into the single lentiviral vector facilitates detection of the presence of the vector in an iPS. The invention provides compositions and methods of producing iPS cells using a single multi-cistronic lentiviral vector. | 09-29-2011 |
20110177534 | DIAGNOSTICS FOR MEMBRANOUS NEPHROPATHY - The invention relates to immunoassays, reagents, therapeutics and methods of diagnosing and prognosis evaluation of idiopathic membranous nephropathy (MN). Immunoassays comprise enzyme-linked immunoabsorbent assays and nephelometric immunoassays for serum auto-antibodies reactive against a phospholipase A2 receptor (PLA2R). Therapeutic methods include removal of the auto-antibodies by absorbance or administration of soluble PLA2R or fragments to sequester the auto-antibodies. | 07-21-2011 |
20110060188 | LOW COST DISPOSABLE MEDICAL FORCEPS TO ENABLE A HOLLOW CENTRAL CHANNEL FOR VARIOUS FUNCTIONALITIES - The present invention relates to an endoscopic biopsy forceps ( | 03-10-2011 |
20110027277 | PREDICTIVE MARKER FOR TOPOISOMERASE I INHIBITORS - The present invention generally relates to the fields of cancer therapy and cancer prevention. More particularly, the present invention generally relates to a diagnostic marker for predicting the efficacy of topoisomerase I (topo I) inhibitors in the treatment of cancers. More specifically, the present invention relates to methods, machines, computer systems, computable readable media and kits which can be used to identify and determine the effectiveness of topoisomerase I (topo I) inhibitors in the treatment of cancers, and in some embodiments, the level of sensitivity or resistance of a tumor cell to a topoisomerase I inhibitor, such as camptothecin (CPT), or CTP analogues such as topotecan and irinotecan and derivatives thereof. More specifically, the present invention related to methods, machines, computer systems, computable readable media and kits which can be used to determine the presence of phosphorylation of topoisomerase I polypeptide, in some embodiments phosphorylation at residue serine 10 (S10) of a topoisomerase I polypeptide, wherein the presence of phosphorylation, in particular the phosphorylation at serine 10 of a topoI polypeptide indicates a cancer is likely to be unresponsive to a topo I inhibitor, whereas the absence of phosphorylation, in particular, the absence of phosphorylation at residue serine 10 (S10) identifies a cancer is likely to be responsive to a topo I inhibitor. Other aspect of the present invention relate to phospho-serine 10 topoisomerase I antibodies and other protein binding moieties, and uses thereof. | 02-03-2011 |
20110014227 | PRE-OR POST-EXPOSURE TREATMENT FOR FILOVIRUS OR ARENAVIRUS INFECTION - The compositions and methods of the invention described herein provide pre- or post-exposure treatments against filovirus or arenavirus infection by expressing one or more genes (e.g., two ore more genes) from filoviruses or arenaviruses in a delivery vehicle (e.g., a recombinant viral vector or a liposome). | 01-20-2011 |
20100203521 | METHOD FOR BACTERIAL LYSIS - The present invention is directed to a microfluidic device for lysis of cells, such as bacteria and microorganisms. In particular, the present invention relates to microfluidic devices and methods of manufacture of such microfluidic devices comprising a substrate with at least one channel packed with a polymer monolith embedded with carbon particles, for example carbon nanotubes. The microfluidic devices and methods of the present invention are useful for cell lysis of cells within a biological sample, such as a untreated biological sample comprising microorganisms, such as but not limited to gram positive and gram negative bacteria. In some embodiments, the microfluidic devices of the present invention can also optionally comprise other modules enabling further processing of the biological sample, for example isolation, purification and detection of biomolecules released from the lysed cells, such as but not limited to nucleic acids or proteins or peptides from the lysed cells, providing a complete Lab-on-a-Chip analysis system for biomolecules released from difficult to lyse microorganisms in a single step or process. The microfluidic devices of the present invention can also be adapted and are useful to methods to enrich for microorganisms in a biological sample, for example enrich for a desired type of bacteria within a biological sample. The microfluidic devices and methods of the present invention can be adapted to perform highly efficient lysis of microorganisms within a biological sample for diagnostic tests, for example for diagnosis of infectious agents and pathogens, such as bacteria, viruses or parasites. | 08-12-2010 |
20090326384 | Device With Integrated Multi-Fiber Optical Probe and Methods of Use - Biopsy instruments are integrated with a multi-fiber optical probe adapted to perform diagnostic measurements. In addition to being able to analyze, treat or remove tissue, such integrated devices characterize tissue by measuring the amount of scattering and absorption of light transmitted into the tissue. Each fiberoptic probe has an illuminating fiber that provides a broadband light source for transmission into tissue, and a collecting fiber that collects the light scattered by the tissue and transmits the collected light to a spectrometer. One embodiment is an endoscope-mediated tool with a jaw-type biopsy forceps and a multi-fiber optical probe which is conveyed through a hollow central channel. Another embodiment is an endoscope-mediated tool with a jaw-type biopsy forceps and a plurality of multi-fiber optical probes. Yet another embodiment is an endoscopic polypectomy-type snare catheter with a multi-fiber optical probe located at the tip. | 12-31-2009 |
20090291883 | COMBINATION OF AN IMMUNOSUPPRESSIVE AGENT AND NONSTEROIDAL ANTI -INFLAMMATORY DRUGS TO TREAT DISEASE - The present invention provides methods and compositions for the treatment and prevention of neoplasia by administering an effective amount of a NSAID in combination with an effective amount of an immunosuppressant agent. In particular, the present invention provides methods and compositions for the treatment and prevention of neoplasia by administering an effective amount of COX-2 inhibitor in combination with an effective amount of an immunosuppressant agent. | 11-26-2009 |
20080249023 | Antibacterial Peptide with Activity Against B. Anthracis - Disclosed is a therapeutic peptide useful in the treatment or prevention of infection caused by Gram-positive bacteria such as | 10-09-2008 |